Fig. 5 | Modern Pathology

Fig. 5

From: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Fig. 5

PD-L1 antibodies bind epitopes in the extracellular and cytoplasmic domains of PD-L1. a Illustration of putative binding epitopes of 22C3 and 28-8 PD-L1 antibodies identified by chemical linkage of peptides on scaffolds discontinuous epitope mapping, hydrogen/deuterium exchange mass spectrometry, and mutational analysis. N35, N192, N200, and N219 represent the locations of N-linked glycosylation sites. b Location of PD-L1 residues mutated during mutation analysis. c SP263 and SP142 bind identical epitopes in the cytoplasmic domain of PD-L1. E1L3N also binds an epitope in the cytoplasmic domain; however, it is different to SP263 and SP142. 22C3 and 28-8 bind epitopes on distinct surfaces of the extracellular domain of PD-L1, which are different from one another. Mutated residues are in red (ECD) and green (CD). CD cytoplasmic domain, CLIPS Chemical Linkage of Peptides onto Scaffolds, ECD extracellular domain, HDX-MS hydrogen deuterium exchange mass spectrometry, Ig immunoglobulin, PD-1 programmed cell death-1, PD-L1 programmed cell death ligand-1, SP signal peptide, TM transmembrane domain

Back to article page